Richard Nieman MD

Dr. Richard Nieman is a pharmaceutical physician with extensive global experience in medical affairs and drug development. He has held senior roles at Bayer, Teva, and Bristol Myers Squibb (BMS), including 5 years as Head of Medical and Global Medical Officer at Teva—at the time, a $21 billion company ranked #13 among global pharmaceutical companies. In that role, he was a member of the Specialty Executive Team and led Teva’s Medical and Health Economics & Outcomes Research (HEOR) organizations, overseeing more than 500 professionals and managing an operating budget of $300 million.

Richard brings a uniquely international perspective, having lived and worked across the US, Europe, the UK, and Asia. He served as BMS’ most senior R&D leader in China immediately prior to the COVID-19 pandemic, where he led all R&D functions and oversaw more than 15 clinical trials, contributing to two new oncology approvals in the Chinese market. He later led the global medical strategy for BMS’ immunology portfolio.
Throughout his career, Richard has led large, complex global teams and organizations, shaping medical strategy across a broad range of therapeutic areas. His responsibilities also included late-phase evidence generation, medical communications, operations, medical governance, and multiple global product launches.

Originally from the UK, Richard is a trained respiratory physician (pulmonologist). He studied medicine at Imperial College London (St Mary’s Hospital) and at the Royal Brompton Hospital, part of the National Heart and Lung Institute—one of Europe’s leading research centres. He is a Fellow of the Royal College of Physicians (UK), was an invited panellist at the World Economic Forum, and was a Visiting Professor at Fudan University in Shanghai, China, within the School of Health Economics and Public Health. Richard is the author of numerous scientific publications and holds multiple patents related to novel drug development. He is passionate about advancing access to innovative medicines for underserved communities.